Whether you are a surgical, medical, or radiation oncologist, the care goals remain the same, that is, achieving a durable treatment response. For patients with localized intermediate-risk prostate cancer undergoing radiation treatment, identifying t...
BACKGROUND: Androgen deprivation therapy (ADT) with radiotherapy can benefit patients with localized prostate cancer. However, ADT can negatively impact quality of life, and there remain no validated predictive models to guide its use. METHODS: We us...
Information on the occurrence and endocrine potencies of analogues of bisphenol A (BPA) and diglycidyl ester derivatives (BDGEs) of BPA and BPF is limited. Such information is, however, important as the current debate on BPA and the lowered BPA migra...
PURPOSE: The aim of this study was to evaluate the effect of salvage radiation therapy (sRT) on survival, functional outcomes, and quality of life in men with persistent prostate-specific antigen (PSA >0.1 ng/mL) after a robot-assisted radical prosta...
BACKGROUND/AIM: The aim of the study was to evaluate the risk of venous thromboembolism (VTE) after robot-assisted radical prostatectomy (RARP) and discuss whether a uniform prophylaxis for VTE after radical prostatectomy is also suitable for robotic...
The object in this study is to develop an artificial intelligence-based deep learning algorithm for prediction of time to castration-resistant prostate cancer by combined androgen blockade therapy in metastatic hormone-naïve prostate cancer. We inclu...
OBJECTIVE: To compare the tumor control in prostate cancer patients with oligo-metastasis following combined robot-assisted radical prostatectomy and androgen deprivation versus androgen deprivation therapy alone based on total prostate-specific anti...
BACKGROUND: Patients with prostate cancer are offered a wide range of treatments from radiation therapy to chemotherapy to surgery. When giving radiation therapy, SpaceOAR hydrogel has been part of the standard treatment for the last decade to reduce...
PURPOSE: The SPARTAN trial demonstrated that the addition of apalutamide to androgen deprivation therapy improves outcomes among patients with nonmetastatic castration-resistant prostate cancer (nmCRPC). We applied a previously reported digital histo...
BACKGROUND: Androgen deprivation therapy (ADT) improves outcomes in men undergoing definitive radiotherapy for prostate cancer but carries significant toxicities. Clinical parameters alone are insufficient to accurately identify patients who will der...